Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotechnology company, has announced its participation in the 2024 Spartan Capital Investor Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotechnology company, has announced its participation in the 2024 Spartan Capital Investor Conference. CEO Jonathan Kaufman, PhD, will deliver a presentation on November 4th, 2024, at 9:25 am EST at the Pierre Hotel in New York. The company, which focuses on addressing serious diseases with significant unmet needs, will also offer one-on-one meetings with registered conference investors.
Details
News Market Reaction – LIPO
The recorded move for LIPO in the trading session of this news was -1.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York.
Event: Lipella Presentation - 2024 Spartan Capital Investor Conference
Date: Monday, November 4th, 2024
Time: 9:25 am EST
Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.
About Lipella Pharmaceuticals
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn
CONTACT
Jeff Ramson
PCG Advisory
jramson@pcgadvisory.com
646-863-6893
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.